Abstract:Stroke is considered as the first cause of neurological dysfunction and second cause of death worldwide. Recombinant tissue plasminogen activator is the only chemical treatment for ischemic stroke approved by the US Food and Drug Administration. It was the only standard of care for a long time with a very narrow therapeutic window, which usually ranges from 3 to 4.5 h of stroke onset; until 2015, when multiple trials demonstrated the benefit of mechanical thrombectomy during the first 6 h. In addition, recent trials showed that mechanical thrombectomy can be beneficial up to 24 h if the patients meet certain criteria including the presence of magnetic resonance imaging/computed tomography perfusion mismatch, which allows better selectivity and higher recruitment of eligible stroke patients. However, magnetic resonance imaging/computed tomography perfusion is not available in all stroke centers. Hence, physicians need other easy and available diagnostic tools to select stroke patients eligible for mechanical thrombectomy. Moreover, stroke management is still challenging for physicians, particularly those dealing with patients with "wake-up" stroke. The resulting brain tissue damage of ischemic stroke and the subsequent pathological processes are mediated by multiple molecular pathways that are modulated by inflammatory markers and post-transcriptional activity. A considerable number of published works suggest the role of inflammatory and cardiac brain-derived biomarkers (serum matrix metalloproteinase, thioredoxin, neuronal and glial markers, and troponin proteins) as well as different biomarkers including the emerging roles of microRNAs. In this review, we assess the accumulating evidence regarding the current status of acute ischemic stroke diagnostic biomarkers that could guide physicians for better management of stroke patients. Our review could give an insight into the roles of the different emerging markers and microRNAs that can be of high diagnostic value in patients with stroke. In fact, the field of stroke research, similar to the field of traumatic brain injury, is in immense need for novel biomarkers that can stratify diagnosis, prognosis, and therapy.

Ischemic stroke biomarkers in blood

Blood biomarkers in ischemic stroke: potential role and challenges in clinical practice and research

Blood-Based Biomarkers Are Associated with Different Ischemic Stroke Mechanisms and Enable Rapid Classification between Cardioembolic and Atherosclerosis Etiologies

Blood biomarkers in the early stage of cerebral ischemia

Biomarkers and the outcomes of ischemic stroke

Progress and potential roles blood biomarkers of ischemic stroke in clinical setting

Stroke Biomarkers: Progress and Challenges for Diagnosis, Prognosis, Differentiation, and Treatment

Clinical application of blood biomarkers in cerebrovascular disease

Molecular biomarkers in stroke diagnosis and prognosis

Evolving role of biomarkers in acute cerebrovascular disease

Acute ischemic stroke biomarkers: a new era with diagnostic promise?

Identification of Serum Biomarkers of Ischemic Stroke in a Hypertensive Population Based on Metabolomics and Lipidomics

Bioinformatics strategies to identify differences in molecular biomarkers for ischemic stroke and myocardial infarction

Multi-Level Biomarkers for Early Diagnosis of Ischaemic Stroke: A Systematic Review and Meta-Analysis

Cerebrospinal Fluid Biomarkers for Diagnosis and the Prognostication of Acute Ischemic Stroke: A Systematic Review

Biomarkers for acute diagnosis and management of stroke in neurointensive care units

A Systematic Review and Meta-Analysis Assessing the Accuracy of Blood Biomarkers for the Diagnosis of Ischemic Stroke in Adult and Elderly Populations

Neurovascular Unit as a Source of Ischemic Stroke Biomarkers—Limitations of Experimental Studies and Perspectives for Clinical Application

Novel inflammatory biomarkers associated with stroke severity: results from a cross-sectional stroke cohort study

Applicability of Biomarkers in Ischemic Stroke

Neuronal plasma biomarkers in acute ischemic stroke